Evidence map›Paper›PMID 10364318›Full record

ArticleJournal of virology1999

Inhibition of herpes simplex virus gD and lymphotoxin-alpha binding to HveA by peptide antagonists.

M R Sarrias, J C Whitbeck, I Rooney, L Spruce, B K Kay, R I Montgomery, P G Spear, C F Ware, R J Eisenberg, G H Cohen and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Compstatin: a complement inhibitor on its way to clinical application.Advances in experimental medicine and biology · 2008
    Review
  2. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway.Proceedings of the National Academy of Sciences of the United States of America · 2005
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

M R SarriasLaboratory of Protein Chemistry, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
J C Whitbeck
I Rooney
L Spruce
B K Kay
R I Montgomery
P G Spear
C F Ware
R J Eisenberg
G H Cohen
J D Lambris
Peptide Protein Research (United Kingdom) · GBLa Jolla Institute for Immunology · USNorthwestern Medicine · USUniversity of Pennsylvania · USUniversity of Wisconsin–Madison · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
VIRAL VECTOR COREP30DK019525 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL A. LAZAR · 1986 to 2026
$48.3M
Studies of Herpes Simplex Virus GlycoproteinsR37AI018289 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI COHEN, GARY H · 2005 to 2014
$3.9M
STUDIES OF HERPES SIMPLEX VIRUS GLYCOPROTEINSR01AI018289 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI COHEN, GARY H · 1985 to 2019
$3.8M
PATHOGNESIS OF MOUSE HEPATITIS CORONAVIRUSP01NS030606 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI GONZALEZ-SCARANO, FRANCISCO A · 1993 to 2002
$3.2M
EARLY EVENTS IN HERPES SIMPLEX VIRUS ENTRYR01NS036731 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI EISENBERG, ROSELYN J · 1997 to 2006
$2.4M
VIRAL RESPIRATORY PATHOGENS RESEARCH UNIT /VRPRU/-266030040-266030040N01AI030040 · NIAID · UNIVERSITY OF IOWA · PI APICELLA, MICHAEL A. · 2003 to 2006
–
NCI NIH HHS P30 CA016520NIAID NIH HHS N01 AI030040NIAID NIH HHS R01 AI018289NIAID NIH HHS R37 AI018289NIDDK NIH HHS P30 DK019525NINDS NIH HHS NS-30606NINDS NIH HHS NS-36731NINDS NIH HHS P01 NS030606NINDS NIH HHS R01 NS036731
6 · The paper itself

Abstract

The herpesvirus entry mediator A (HveA) is a recently characterized member of the tumor necrosis factor receptor family that mediates the entry of most herpes simplex virus type 1 (HSV-1) strains into mammalian cells. Studies on the interaction of HSV-1 with HveA have shown that of all the viral proteins involved in uptake, only gD has been shown to bind directly to HveA, and this binding mediates viral entry into cells. In addition to gD binding to HveA, the latter has been shown to interact with proteins of tumor necrosis factor receptor-associated factor family, lymphotoxin-alpha (LT-alpha), and a membrane-associated protein referred to as LIGHT. To study the relationship between HveA, its natural ligands, and the viral proteins involved in HSV entry into cells, we have screened two phage-displayed combinatorial peptide libraries for peptide ligands of a recombinant form of HveA. Affinity selection experiments yielded two peptide ligands, BP-1 and BP-2, which could block the interaction between gD and HveA. Of the two peptides, only BP-2 inhibited HSV entry into CHO cells transfected with an HveA-expressing plasmid. When we analyzed these peptides for the ability to interfere with HveA binding to its natural ligand LT-alpha, we found that BP-1 inhibited the interaction of cellular LT-alpha with HveA. Thus, we have dissected the sites of interaction between the cell receptor, its natural ligand LT-alpha and gD, the virus-specific protein involved in HSV entry into cells.

Indexed as

Amino Acid SequenceAnimalsBacteriophagesBinding, CompetitiveCarrier ProteinsCell LineCHO CellsCricetinaeLigandsLymphotoxin-alphaMolecular Sequence DataPeptidesReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Member 14Receptors, VirusRecombinant Fusion ProteinsCarrier Proteinsglycoprotein D, Human herpesvirus 1HevA-binding peptide BP-1HevA-binding peptide BP-2LigandsLymphotoxin-alphaPeptidesReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Member 14Receptors, VirusRecombinant Fusion ProteinsTNFRSF14 protein, humanViral Envelope Proteins

Identifiers

PMID10364318
PMCPMC112627
OpenAlexW2159542789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.